Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Modality
UNKNOWN
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fatty Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Extra Virgin Olive Oil (this asset) | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis | N/A | D · 30 |
| Metformin | Leiden University Medical Center | P4 | BB |
| Alpha Tocopherol | Yuen Kah Hay | P4 | BB |
| Liraglutide | Leiden University Medical Center | P4 | BB |
| Raltegravir | Helsinki University Central Hospital | P4 | BB |
| Pioglitazone | Seoul National University Bundang Hospital | P4 | BB |
| Empagliflozin | Seoul National University Bundang Hospital | P4 | BB |
| Rilpivirine | Fundacion SEIMC-GESIDA | P4 | B |
| Dolutegravir | Fundacion SEIMC-GESIDA | P4 | B |
+42 more in the Fatty Liver Disease cohort
Other indications for Extra Virgin Olive Oil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cognitive Disorder | — | P2 | CC · 47 |
| Cerebral Amyloid Angiopathy | — | Unk | D · 30 |
| Abdominal Obesity-Metabolic Syndrome | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Extra Virgin Olive Oil in Fatty Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/extra-virgin-olive-oil-fatty-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →